Centocor offers new shares to repay debt
This article was originally published in Clinica
Executive Summary
US biotechnology company Centocor expects to net $109 million from an offering of 3.5 million new shares which could increase to $125 million if the underwriters' over-allotment option is exercised in full. A price of $32.88 a share has been assumed in the prospectus.